Prorenata Biotech is committed to accelerating the development and transition of gene-based therapeutics and vaccines to the clinics. Many potent and promising therapeutics are left sitting on laboratory benches waiting for means of translations to become available. Prorenata Biotech is devoted to supporting the development of gene-based therapeutics from the early stages of conceptualisation, all the way to tailoring custom solutions for its delivery in living organisms. We believe in innovation, quality, and accessibility of therapeutics for everyone.
We are experts in CRISPR, Lipid Nanoparticles, and Genetic Medicine. Our mission is to lower the barrier for researchers to access novel approaches for moving their discoveries forward to benefit people struggling with health conditions that are yet to be addressed. We do this by bridging the gap between laboratory research and biotechnology, with a focus on gene-editing, nanotechnology, and molecular biology.